Individualized Hypertension Management in Chronic Kidney Disease

Authored by Sourabh Sharma, published on 2026-11-18 20:15:55.0

  1. Confirm BP With Standardized Office, Orthostatic, HBPM, or ABPM Measurements
    • Hypertensive Emergency With Acute Target-Organ Injury?
      • Admit and Start IV BP Therapy Tailored to Organ Injury
      • Stage G1–G5/A1–A3; Assess Diabetes, CV Risk, Volume, Frailty, Electrolytes, and Secondary Causes
        • Which CKD Treatment Population Applies?
          • Can an Intensive Guideline Target Be Safely Tolerated?
            • Use KDIGO Standardized SBP Below 120, ESC 120–129/70–79, or AHA Below 130/80
              • Albuminuria A2–A3, Heart Failure, or Another RAS Indication?
                • Start One ACEI or ARB and Titrate to Maximally Tolerated Dose
                  • Optimize Lifestyle and Volume; Complete RAS Blocker, DHP CCB, and Effective Diuretic Regimen
                    • Recheck BP, Orthostasis, Creatinine, eGFR, and Potassium Within 2–4 Weeks of Drug Changes
                      • BP at Target and Treatment Tolerated?
                        • Continue Therapy With Risk-Based BP, Kidney Function, and Electrolyte Monitoring
                        • Treat Hyperkalemia; Investigate Creatinine Rise ≥30%; Hold or Reduce Drugs for Persistent Toxicity
                        • Confirm Resistance, Correct Pseudoresistance, Evaluate Secondary Causes, Add Population-Appropriate Therapy, and Refer
                        • Intensify Population-Specific Therapy, Then Reassess BP, Orthostasis, Kidney Function, and Potassium
                • Start DHP CCB or Diuretic; Use Initial Combination Therapy When Appropriate
                  • Optimize Lifestyle and Volume; Complete RAS Blocker, DHP CCB, and Effective Diuretic Regimen
                    • Recheck BP, Orthostasis, Creatinine, eGFR, and Potassium Within 2–4 Weeks of Drug Changes
                      • BP at Target and Treatment Tolerated?
                        • Continue Therapy With Risk-Based BP, Kidney Function, and Electrolyte Monitoring
                        • Treat Hyperkalemia; Investigate Creatinine Rise ≥30%; Hold or Reduce Drugs for Persistent Toxicity
                        • Confirm Resistance, Correct Pseudoresistance, Evaluate Secondary Causes, Add Population-Appropriate Therapy, and Refer
                        • Intensify Population-Specific Therapy, Then Reassess BP, Orthostasis, Kidney Function, and Potassium
            • Use Less Intensive Symptom-Limited Target for Frailty, Orthostasis, or Limited Prognosis
              • Albuminuria A2–A3, Heart Failure, or Another RAS Indication?
                • Start One ACEI or ARB and Titrate to Maximally Tolerated Dose
                  • Optimize Lifestyle and Volume; Complete RAS Blocker, DHP CCB, and Effective Diuretic Regimen
                    • Recheck BP, Orthostasis, Creatinine, eGFR, and Potassium Within 2–4 Weeks of Drug Changes
                      • BP at Target and Treatment Tolerated?
                        • Continue Therapy With Risk-Based BP, Kidney Function, and Electrolyte Monitoring
                        • Treat Hyperkalemia; Investigate Creatinine Rise ≥30%; Hold or Reduce Drugs for Persistent Toxicity
                        • Confirm Resistance, Correct Pseudoresistance, Evaluate Secondary Causes, Add Population-Appropriate Therapy, and Refer
                        • Intensify Population-Specific Therapy, Then Reassess BP, Orthostasis, Kidney Function, and Potassium
                • Start DHP CCB or Diuretic; Use Initial Combination Therapy When Appropriate
                  • Optimize Lifestyle and Volume; Complete RAS Blocker, DHP CCB, and Effective Diuretic Regimen
                    • Recheck BP, Orthostasis, Creatinine, eGFR, and Potassium Within 2–4 Weeks of Drug Changes
                      • BP at Target and Treatment Tolerated?
                        • Continue Therapy With Risk-Based BP, Kidney Function, and Electrolyte Monitoring
                        • Treat Hyperkalemia; Investigate Creatinine Rise ≥30%; Hold or Reduce Drugs for Persistent Toxicity
                        • Confirm Resistance, Correct Pseudoresistance, Evaluate Secondary Causes, Add Population-Appropriate Therapy, and Refer
                        • Intensify Population-Specific Therapy, Then Reassess BP, Orthostasis, Kidney Function, and Potassium
          • Use Interdialytic ABPM or HBPM; Individualize Goal and Avoid Intradialytic Hypotension
            • Optimize Dry Weight; Use HD Beta-Blocker or DHP CCB, or PD ACEI or ARB
              • Recheck BP, Orthostasis, Creatinine, eGFR, and Potassium Within 2–4 Weeks of Drug Changes
                • BP at Target and Treatment Tolerated?
                  • Continue Therapy With Risk-Based BP, Kidney Function, and Electrolyte Monitoring
                  • Treat Hyperkalemia; Investigate Creatinine Rise ≥30%; Hold or Reduce Drugs for Persistent Toxicity
                  • Confirm Resistance, Correct Pseudoresistance, Evaluate Secondary Causes, Add Population-Appropriate Therapy, and Refer
                  • Intensify Population-Specific Therapy, Then Reassess BP, Orthostasis, Kidney Function, and Potassium
          • Target Below 130/80 and Assess Graft Dysfunction, Calcineurin Effects, and Transplant-Specific Causes
            • Start DHP CCB or ARB; Individualize for Albuminuria and Graft Function
              • Recheck BP, Orthostasis, Creatinine, eGFR, and Potassium Within 2–4 Weeks of Drug Changes
                • BP at Target and Treatment Tolerated?
                  • Continue Therapy With Risk-Based BP, Kidney Function, and Electrolyte Monitoring
                  • Treat Hyperkalemia; Investigate Creatinine Rise ≥30%; Hold or Reduce Drugs for Persistent Toxicity
                  • Confirm Resistance, Correct Pseudoresistance, Evaluate Secondary Causes, Add Population-Appropriate Therapy, and Refer
                  • Intensify Population-Specific Therapy, Then Reassess BP, Orthostasis, Kidney Function, and Potassium
  2. Independent Reference Module: Never Apply KDIGO SBP Below 120 to Routine Nonstandardized Clinic BP
  3. Independent Reference Module: Advanced CKD Loop Diuretic or Closely Monitored Chlorthalidone
  4. Independent Reference Module: Add MRA for Non-Dialysis Resistant Hypertension When Safe
  5. Independent Reference Module: Add Indicated SGLT2 Inhibitor and Finerenone in Diabetic Albuminuric CKD
  6. Independent Reference Module: Refer for Progression, Secondary Causes, Refractory BP, or Recurrent Toxicity
tosprivacy